Pricing, patents and the PMPRB in Canada

The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Canada's drug pricing plan prompts backlash

26 October 2020 The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Americas

Generics in Canada: The race for market exclusivity

3 March 2015 Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Trump’s march-in rights threat: Why pharma is rethinking collaborations

GSK escalates mRNA COVID-19 vaccine dispute

The flaw that landed Sanofi a win in the rare disease space

Pricing, patents and the PMPRB in Canada

More on this story

Editor's picks

Editor's picks

More features